- Scope of the procurement
- Lot 18 - Fresh Frozen Plasma
- Lot 16 - Prothrombin Complex dried
- Lot 15 - Fibrinogen Concentrate
- Lot 14 - Von willebrands factor - Recombinant
- Lot 17 - Protein C Concentrate
- Lot 10 - Factor XIII - Plasma Derived
- Lot 11 - Factor XIII - Recombinant
- Lot 9 - Factor X
- Lot 8 - Factor IX - High Purity Factor IX
- Lot 7 - Factor eight Inhibitor Bypassing Fraction
- Lot 13 - Von willebrands factor - Plasma Derived
- Lot 12 - Factor eight/ von willebrands factor
- Lot 6 - Porcine Factor eight - susoctocog alfa
- Lot 5 - Recombinant Factor seven
- Lot 4 - rFIX - Standard Half Life
- Lot 3 - nonacog beta pegol (rFIX EHL)
- Lot 2 - albutrepenonacog alfa (rFIX EHL)
- Lot 1 - eftrenonacog alfa (rFIX EHL)
Section one: Contracting authority
one.1) Name and addresses
The NHS Commissioning Board (operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
Contact
Philip Grieve
Country
United Kingdom
NUTS code
UK - United Kingdom
Internet address(es)
Main address
Buyer's address
one.2) Information about joint procurement
The contract is awarded by a central purchasing body
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
Tenders or requests to participate must be submitted to the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B
Reference number
CM/PHS/19/5576
two.1.2) Main CPV code
- 33141530 - Blood coagulants
two.1.3) Type of contract
Supplies
two.1.4) Short description
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.1.5) Estimated total value
Value excluding VAT: £500,000,000
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for all lots
two.2) Description
two.2.1) Title
Lot 18 - Fresh Frozen Plasma
Lot No
18
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 16 - Prothrombin Complex dried
Lot No
16
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 15 - Fibrinogen Concentrate
Lot No
15
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 14 - Von willebrands factor - Recombinant
Lot No
14
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 17 - Protein C Concentrate
Lot No
17
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 10 - Factor XIII - Plasma Derived
Lot No
10
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 11 - Factor XIII - Recombinant
Lot No
11
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 9 - Factor X
Lot No
9
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 8 - Factor IX - High Purity Factor IX
Lot No
8
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 7 - Factor VIII Inhibitor Bypassing Fraction
Lot No
7
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 13 - Von willebrands factor - Plasma Derived
Lot No
13
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 12 - Factor VIII/ von willebrands factor
Lot No
12
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 6 - Porcine Factor VIII - susoctocog alfa
Lot No
6
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 5 - Recombinant Factor VII
Lot No
5
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 4 - rFIX - Standard Half Life
Lot No
4
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 3 - nonacog beta pegol (rFIX EHL)
Lot No
3
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 2 - albutrepenonacog alfa (rFIX EHL)
Lot No
2
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 1 - eftrenonacog alfa (rFIX EHL)
Lot No
1
two.2.2) Additional CPV code(s)
- 33141530 - Blood coagulants
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
two.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2022
End date
30 June 2024
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section three. Legal, economic, financial and technical information
three.1) Conditions for participation
three.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
three.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
14 February 2022
Local time
1:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until: 15 May 2022
four.2.7) Conditions for opening of tenders
Date
14 February 2022
Local time
1:00pm
Place
Runcorn
Information about authorised persons and opening procedure
Commercial Medicines Unit Employee
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
six.3) Additional information
RESPONDING TO THIS NOTICE:
Any supplier may be disqualified who does not respond to the following in the requisite manner:
1) Submission of expression of interest and procurement specific information
This procurement exercise will be conducted on the eTendering portal at
https://healthfamily.force.com/s/Welcome
Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific
information (if requested) through the eTendering portal as follows:
1.1) If not already registered, Candidatesshould register on the eTendering portal at
https://health-family.force.com/s/Welcome and
click the link to register:
- agree to the user agreement
- populate company details
1.2) Once registered, candidates must register interest as follows:
- log to the portal
- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select
review opportunity details and click "Register Interest"
- as you select the opportunity, you can review documents, send clarification messages,submit the response or decline to respond (if
you decide not to participate in the opportunity)
1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at supporthealth@
atamis.co.uk or by calling 0800 9956035 for technical assistance when
completing responses.
2) General supplier information.
To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:
2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the
following web page
https://supplierregistration.cabinetoffice.gov.uk and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S®Number, click on the link at the right of the page to obtain a number from D&B.
Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.
2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.
D&B data will be supplied automatically by D&B.
2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.
OTHER CONTRACTING AUTHORITIES
The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together
as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or
goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare
or health related services.
six.4) Procedures for review
six.4.1) Review body
The High Court
Strand
London
WC2A 2LL
generaloffice@administrativecourtoffice.justice.gov.uk
Country
United Kingdom